SPARS
2025–2028

In the SPARS scenario, the pathogen is St. Paul Acute Respiratory Syndrome Coronavirus (SPARS-CoV) — a novel coronavirus that jumps from animal reservoirs (likely through contact with infected livestock or domesticated animals in Southeast Asia) to humans.

The index case traces to a group of church members from St. Paul, Minnesota who traveled to the Philippines on a mission trip. Several members become ill upon return, and two die within weeks. CDC identifies the pathogen as a new coronavirus distinct from SARS-CoV and MERS-CoV.

The virus spreads primarily through respiratory droplets and has an initial estimated case fatality rate of 4.7% — later revised down to 0.6% as more data becomes available. This revision itself becomes a major communication crisis.

Notably, this scenario was published in 2017 — three years before SARS-CoV-2 (COVID-19) emerged. The parallels are striking: a novel coronavirus, animal reservoir origins, respiratory transmission, evolving fatality estimates, and a global pandemic requiring emergency vaccine development.

Corovax is the fictional SPARS vaccine, developed by pharmaceutical company CynBio. Its development was fast-tracked after researchers at GMI (a livestock conglomerate) identified a promising animal coronavirus vaccine model that could be adapted for humans.

The vaccine was authorized under the PREP Act (Public Readiness and Emergency Preparedness Act), which provides legal liability protection for manufacturers during public health emergencies. This legal shield became a source of public controversy.

The nationwide rollout beginning in July 2026 triggered intense prioritization debates. Different states adopted different priority lists. Some prioritized children and pregnant women; others prioritized healthcare workers and the elderly. Protests erupted at vaccination sites.

Most critically, by May 2027, reports of long-term neurological side effects began surfacing. Lawsuits were filed. The government faced an agonizing dilemma: how to compensate vaccine-injured individuals without undermining the vaccination program that had saved millions of lives. This chapter — perhaps the most prescient of the entire scenario — anticipated the real-world debates about COVID-19 vaccine injury compensation that would unfold years later.

Kalocivir is an existing broad-spectrum antiviral drug in the SPARS scenario. When SPARS-CoV emerged, there was no proven treatment, so the FDA issued an Emergency Use Authorization for Kalocivir based on limited evidence of potential efficacy.

The drug’s rollout became a case study in communication failure. Initial messaging was overly optimistic, creating expectations the drug couldn’t meet. When it was distributed to the Navajo Nation without culturally appropriate communication, it triggered a backlash that damaged trust in the broader health response.

A viral video (Chapter 5: “Going Viral”) of a child vomiting after taking Kalocivir spread across social media, becoming the defining image of the drug — despite the vomiting being unrelated to the medication. The government’s slow response to the video allowed anti-treatment narratives to solidify.

Later, new data showed Kalocivir was less effective than initially believed (Chapter 9: “Changing Horses Midstream”). This revision, while scientifically appropriate, was perceived as government dishonesty — a pattern that would repeat with COVID-19 treatments like hydroxychloroquine and ivermectin years later.

The SPARS scenario identified information fragmentation as one of the most dangerous dynamics of a pandemic. By 2025, the scenario imagined a media landscape where people consumed news exclusively from sources that confirmed their existing beliefs.

Anti-vaccine leader Alyssa Karpowitz built a powerful movement by exploiting every government mistake: the Kalocivir overpromise, the viral vomiting video, the CFR revision, the vaccine prioritization chaos, and finally the neurological side effects. Each failure fed the echo chamber.

The government compounded the problem by neglecting emerging platforms. Chapter 8 (“Are You Talking to Me?”) describes how officials focused messaging on traditional media while college students organized vaccine resistance on UNEQL — a new social platform the government hadn’t even heard of.

The scenario anticipated the “infodemic” concept that WHO would later use during COVID-19. It predicted with remarkable accuracy how misinformation, echo chambers, and viral content would undermine public health measures — sometimes more effectively than the virus itself.

Chapter 10 (“Head of the Line Privileges”) explores one of the most contentious issues in pandemic response: vaccine prioritization. With limited initial supply, decisions about who receives the vaccine first become life-and-death ethical dilemmas.

The scenario explores tensions between prioritizing children (who spread the virus in schools), pregnant women (a vulnerable group), healthcare workers (needed to treat others), and the elderly (highest mortality risk). No allocation framework satisfies everyone.

Chapter 11 (“Standing in Line, Protesting Online”) adds another dimension: the use of Electronic Health Records (EHR) to manage vaccine distribution. While efficient, this approach triggers privacy concerns and accusations that the government is using medical records for surveillance.

Chapter 15 (“Are You Talking to Me, Part II”) extends the equity debate globally, with college students protesting that wealthy nations are hoarding vaccines while developing countries go without — a dynamic that played out almost identically during COVID-19 with the COVAX initiative.

The final chapters of SPARS may be its most important. Chapter 17 (“Vaccine Injury”) describes the emergence of reports linking Corovax to long-term neurological damage. Class-action lawsuits are filed. The government must balance transparency with maintaining the vaccination program.

Chapter 18 (“Acknowledging Loss”) argues that after a pandemic, political leaders must publicly recognize the emotional toll on the nation — the deaths, the sacrifices, the economic devastation, and the mistakes made by government institutions.

Chapter 19 (“SPARS Aftermath”) describes the long-term political and social fallout. Conspiracy theories about the pandemic’s origins flourish. Some claim SPARS was engineered. Others claim the vaccine was part of a government control program. Trust in public health institutions is damaged for a generation.

The scenario ends not with resolution, but with an open question: how do societies rebuild institutional trust after a crisis that exposed every weakness in their information systems, governance structures, and social contracts? It is a question the post-COVID world is still trying to answer.